Is Brimonidine + Timolol registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 2 valid registrations of Brimonidine + Timolol, including BRIMOCOM (5,2 mg/ml,mg/ml, Eye drops, SAR 38.65); COMBIGAN (5,2 mg/ml,mg/ml, Eye drops, SAR 31.80).

Is Brimonidine + Timolol approved by the US FDA?

Drugs@FDA lists 13 application product lines for Brimonidine + Timolol, including COMBIGAN (Prescription); BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (Prescription); BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (Prescription); BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (Prescription); BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (Prescription).

Active substances

Brimonidine + Timolol

SFDA 2
US FDA 13
Health Canada 3
US price lines 6
NHS prices 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
BRIMOCOM	5,2 mg/ml,mg/ml	Eye drops · Ocular use	1 Bottle	SAR 38.65	Generic · Prescription	Jamjoom Pharmaceuticals Factory Company	Valid
COMBIGAN	5,2 mg/ml,mg/ml	Eye drops · Ophthalmic use	1 Dropper Container	SAR 31.80	NCE · Prescription	ABBVIE LIMITED	Valid

Indications — CHI Daman Drug Formulary

OPEN ANGLE GLUCOMA

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
COMBIGAN	0.2%;EQ 0.5% BASE	solution/drops · ophthalmic	ABBVIE	Prescription	30 Oct 2007
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE	0.2%;EQ 0.5% BASE	solution/drops · ophthalmic	SANDOZ	Prescription	4 Apr 2022
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE	0.2%;EQ 0.5% BASE	solution/drops · ophthalmic	APOTEX	Prescription	20 Apr 2022
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE	0.2%;EQ 0.5% BASE	solution/drops · ophthalmic	REGCON HOLDINGS	Prescription	4 Oct 2022
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE	0.2%;EQ 0.5% BASE	solution/drops · ophthalmic	SENTISS	Prescription	31 Oct 2022
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE	0.2%;EQ 0.5% BASE	solution/drops · ophthalmic	UPSHER SMITH LABS	Prescription	12 Dec 2022
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE	0.2%;EQ 0.5% BASE	solution/drops · ophthalmic	ALEMBIC	Prescription	25 Aug 2023
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE	0.2%;EQ 0.5% BASE	solution/drops · ophthalmic	GLENMARK PHARMS LTD	Prescription	16 May 2024
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE	0.2%;EQ 0.5% BASE	solution/drops · ophthalmic	SOMERSET	Prescription	10 Sep 2024
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE	0.2%;EQ 0.5% BASE	solution/drops · ophthalmic	CAPLIN	Prescription	25 Feb 2025
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE	0.2%;EQ 0.5% BASE	solution/drops · ophthalmic	GLAND	Prescription	11 Jun 2026
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE	0.2%;EQ 0.5% BASE	solution/drops · ophthalmic	SABA ILAC SANAYIVE	Prescription	1 Jul 2026
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE	0.2%;EQ 0.5% BASE	solution/drops · ophthalmic	AMNEAL	Discontinued	30 Dec 2024

Canada Canada — marketed products (Health Canada)

Brand	DIN	Strength	Form · route	Company
APO-BRIMONIDINE-TIMOP	02375311	0.2 %; 0.5 %	SOLUTION · OPHTHALMIC	APOTEX INC
COMBIGAN	02248347	0.2 % / W/V; 0.5 % / W/V	SOLUTION · OPHTHALMIC	ABBVIE CORPORATION
JAMP BRIMONIDINE/TIMOLOL	02531704	0.5 % / W/V; 0.2 % / W/V	SOLUTION · OPHTHALMIC	JAMP PHARMA CORPORATION

Prices — United States and England

Source	Product as listed	Price	Unit / pack	Date
US NADAC	BRIMONIDINE-TIMOLOL 0.2%-0.5%	$2.15126	per ML	23 Sep 2026
US NADAC	BRIMONIDINE-TIMOLOL 0.2%-0.5%	$2.71747	per ML	23 Sep 2026
US NADAC	BRIMONIDINE-TIMOLOL 0.2%-0.5%	$1.97168	per ML	23 Sep 2026
US NADAC	COMBIGAN 0.2%-0.5% EYE DROPS	$39.15623	per ML	23 Sep 2026
US NADAC	COMBIGAN 0.2%-0.5% EYE DROPS	$39.09588	per ML	23 Sep 2026
US NADAC	COMBIGAN 0.2%-0.5% EYE DROPS	$39.09128	per ML	23 Sep 2026
NHS Drug Tariff	Brimonidine 2mg/ml / Timolol 5mg/ml eye drops	£15.18	5 ml	1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.